Found 51 Solid Tumors trials
A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate …
A Phase 1/2a dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with advanced metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy, or prior standard of care therapy …
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
The purpose of this study is to continue to collect long term information on the safety of pembrolizumab or pembrolizumab-based combinations that you received or are receiving as part of the protocol you are currently enrolled in, to see how well the drug/s work and how your body reacts to …
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors. We would like to rely on Advarra as the IRB of record for this study.
Please refer to Protocol Section 3.1 (Study Objectives). Please refer to Protocol 3.2 (Study Endpoints). Please refer to Protocol 3.2 (Study Endpoints).
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST …
Primary: To determine the preliminary efficacy of TATE in the locoregional treatment of NET liver metastases using ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 and the DoR. Secondary: Determine the toxicity of TATE in NET patients with liver-dominant metastases Determine the PFS by mRECIST and …
A study designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients with surface accessible solid tumors for which there is a scheduled surgical intervention.
